Clinical Trial

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate development platformsVANCOUVER,…

4 months ago

Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada

  To potentially include adolescents and antibody persistence up to two years Saint Herblain (France), September 18, 2024 – Valneva SE…

4 months ago

Kairos Pharma Closing of $6.2 Million Initial Public Offering

LOS ANGELES, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (“Kairos Pharma” or the “Company”) (NYSE American: KAPA), a…

4 months ago

Therma Bright Announces Shares for Debt Issuance to Include Portfolio Company AI4LYF & IR Agreement

Toronto, Ontario--(Newsfile Corp. - September 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"),…

4 months ago

Xtant Medical Expands Product Portfolio with Launch of its own Viable Bone Matrix, OsteoVive(R) Plus

New Cellular Bone Matrix Designed with Cohesive and Moldable Handling Characteristics BELGRADE, MT / ACCESSWIRE / September 18, 2024 /…

4 months ago

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata raises approximately $7.8 million in gross proceeds since May 2024 - expected to fund its operations into the second…

4 months ago

Aspirion Welcomes Brian Lefort as Chief Human Resources Officer

COLUMBUS, Ga., Sept. 17, 2024 /PRNewswire/ -- Aspirion, a technology-leading healthcare revenue cycle management ("RCM") company for denials, payment variance, and…

4 months ago

Metabolon Expands Integrated Bioinformatics Platform to Include Advanced Statistical Analysis Tool

New tool plays a critical role in supporting complex multiomic research initiatives by helping scientists design and execute customized statistical…

4 months ago

Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA

Ainos Plans To Conduct the Study at National Taiwan University Hospital, a Premier Taiwanese Medical Center for HIV ManagementThe U.S.…

4 months ago